Highlights

  • Mesoblast Ltd (ASX:MSB) is focused on developing and commercialising allogeneic cellular medicines for inflammatory and immune-related conditions.
  • FY26 Revenue increased to US$120.3 million, supported by commercial sales of Ryoncil.
  • Ryoncil generated US$115.2 million in net revenue during FY26 following its commercial launch.
  • MSB shares were trading at AUD 2.06 on 17 September 2026, up 0.98% during the session.

Mesoblast Ltd (ASX:MSB) is a biotechnology company focused on developing cell therapy products for inflammatory diseases, immune disorders and other medical conditions. The company’s FY26 results highlighted commercial progress from Ryoncil, continued Investment in clinical programs and ongoing development of its broader cell therapy pipeline. (Mesoblast)

MSB shares were trading at AUD 2.06 on 17 September 2026, up 0.98% during the session. The share price movement reflects market trading activity, while Mesoblast’s operational focus remains on commercialising approved therapies, advancing clinical programs and expanding its cellular medicine platform.

Ryoncil Commercialisation Becomes Central to Mesoblast’s Healthcare Platform

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell technology platform. The company’s programs target inflammatory, immune and regenerative medicine applications.

A major focus for Mesoblast has been Ryoncil, a cell therapy product developed for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients. The commercial launch of Ryoncil has shifted the company’s focus from primarily clinical development towards product commercialisation and market adoption.

Alongside Ryoncil, Mesoblast continues advancing its broader pipeline, including rexlemestrocel-L for chronic low back pain and other cell therapy programs.

The company’s Business model combines commercial product revenue with continued investment in Research and Development activities aimed at expanding its therapeutic applications.

FY26 Results Reflect Commercial Revenue Growth and Pipeline Investment

Mesoblast reported FY26 revenue of US$120.3 million, compared with US$17.2 million in the previous year. Ryoncil contributed US$115.2 million in net revenue during the period following its commercial launch. (GlobeNewswire)

The company reported Gross Profit of US$103.6 million for FY26, while gross profit excluding Amortisation was US$109.7 million. Research and development expenditure increased during the period as Mesoblast continued investment across its product development programs, Clinical Trials and regulatory activities. (GlobeNewswire)

Mesoblast reported a net loss of US$57.5 million for FY26, compared with a net loss of US$102.1 million in the previous corresponding period. Operating cash spend was US$43.8 million, and the company ended the period with a cash balance of US$102.9 million. (GlobeNewswire)

During FY26, Mesoblast also continued progressing clinical activities, including its Phase 3 trial evaluating rexlemestrocel-L for chronic low back pain. The company reported completion of patient treatment milestones associated with the trial during the year. (Mesoblast)

Clinical Pipeline and Regulatory Progress Shape Future Direction

Mesoblast operates within the biotechnology sector, where product development depends on clinical outcomes, regulatory processes, Manufacturing capability and commercial execution.

The company’s future activities are linked to expanding the use of existing products while progressing additional therapies through clinical development.

Ryoncil remains a key commercial focus, with the company working on market adoption and potential expansion into additional patient groups. Other pipeline programs, including rexlemestrocel-L, remain important areas of development activity.

Biotechnology companies also face challenges related to clinical trial timelines, regulatory requirements, manufacturing scale-up and healthcare market access.

For Mesoblast, maintaining commercial execution while continuing investment in research programs remains a key part of its operating strategy.

What Investors May Watch

Future updates from Mesoblast may include Ryoncil sales performance, regulatory developments, progress across clinical programs and additional information regarding pipeline expansion.

Investors may monitor commercial adoption of Ryoncil, clinical trial outcomes, research and development spending and the company’s cash position.

Further financial reporting periods will provide additional information on revenue growth, operating performance and progress across the company’s therapeutic programs.

Conclusion

Mesoblast enters its next phase with a commercial product platform supported by Ryoncil revenue and a broader pipeline of cell therapy programs. FY26 marked a period of increased revenue generation alongside continued investment in clinical development.

The company’s future progress will depend on commercial execution, clinical outcomes, regulatory milestones and the ability to advance its cellular medicine portfolio.